InvestorsHub Logo
Followers 70
Posts 11769
Boards Moderated 0
Alias Born 01/05/2018

Re: TheDane post# 217167

Monday, 02/12/2018 8:42:34 PM

Monday, February 12, 2018 8:42:34 PM

Post# of 403752
Here's what I can say in quick fashion:

Brilacidin 3 known Indications - Annual (Very Conservative) Possible Market Value Sales for all 3 = 4 Billion

Prurisol - 1 known indication - Annual (Very Conservative) Possible Market Value Sales = 3 Billion

So for just the 2 Drugs Candidates I see at least 7 Billion annual in sales possible (again very conservative)

Let's say BP is looking for 5 year payback (figuring 1 year for Phase 3 trials and 1 year FDA approval process)

If both drug candidates once approved and selling for 3 years bring in 21 Billion (after the 2 years of trials/FDA approval process)

Let's say patents allow for 7 years exclusivity = 7 years x $21B = 147 Billion Total for BP buying IPIX

Let's say Fully Dilluted stock = 200 million shares x $100 per share = $20 Billion

So - and this is just something quick based off of what we know and what I think each drug indication (conservatively) will generate via sales annually - Your telling me that a BP would not pay $20 Billion for a possible $127 Billion + return ( $147 Billion - $20 Billion purchase = $127 Billion)

Now of course the BP's team would need to comb thru all the Phase 2's to see if they feel confident about what the Phase 3's test results would return.